A prospective randomised multicentre phase III clinical trial comparing the effects of PANOREX [edrecolomab] injection plus 5-fluorouracil (5-FU)/leucovorin [folinic acid] versus 5-fluorouracil/leucovorin versus PANOREX alone, in patients with surgically resected stage III (Dukes C) carcinoma of the colon
Latest Information Update: 20 Aug 2023
At a glance
- Drugs Edrecolomab (Primary) ; Fluorouracil; Folinic acid
- Indications Colon cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 19 Feb 2006 New trial record.